Report overview
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment. This report contains market size and forecasts of Chemotherapy Induced Peripheral Neuropathy Treatment in global, including the following market information:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Chemotherapy Induced Peripheral Neuropathy Treatment companies in 2022 (%)
The global Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at US$ 1723.6 million in 2022 and is projected to reach US$ 2613.1 million by 2029, at a CAGR of 6.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
We surveyed the Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Type, 2022 (%)
Calcium Channel ?2-delta Ligands
Antidepressants
Opioids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, by Application, 2022 (%)
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment revenues share in global market, 2022 (%)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Chemotherapy Induced Peripheral Neuropathy Treatment sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chemotherapy Induced Peripheral Neuropathy Treatment, market overview.
Chapter 2: Global Chemotherapy Induced Peripheral Neuropathy Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chemotherapy Induced Peripheral Neuropathy Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Chemotherapy Induced Peripheral Neuropathy Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
